Showing results (181-190 of 223) with videos related to
Sort By:
Pageof 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2019
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin LymphomaIan W Flinn, Carole B Miller, Kirit M Ardeshna, et al.Blood|November 10, 2020
miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitorsSonali Sharma, Gabriela Mladonicka Pavlasova, Vaclav Seda, et al.American Journal of Hematology|February 12, 2024
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemiaKeith W Pratz, Brian A Jonas, Vinod Pullarkat, et al.Leukemia|June 14, 2024
Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugsEva Hoferkova, Vaclav Seda, Sona Kadakova, et al.Bone Marrow Transplantation|December 4, 2025
Frequency and impact of somatic co-occurring mutations on post-transplant outcomes in acute myeloid leukemia: a multicenter registry analysis on behalf of the EBMT ALWPAli Bazarbachi, Jacques-Emmanuel Galimard, Iman Abou Dalle, et al.Clinical Lymphoma, Myeloma & Leukemia|June 23, 2021
IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) StudySarah Lawless, Giulia Sbianchi, Curly Morris, et al.The Lancet. Oncology|December 15, 2015
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 studyAsher Chanan-Khan, Paula Cramer, Fatih Demirkan, et al.The New England Journal of Medicine|April 13, 2022
Rilzabrutinib, an Oral BTK Inhibitor, in Immune ThrombocytopeniaDavid J Kuter, Merlin Efraim, Jiri Mayer, et al.Blood Advances|June 5, 2023
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized studyPierre Fenaux, Marco Gobbi, Patricia L Kropf, et al.Pageof 23